EUVIMEDEUVIMED entdecken
Crossref

Discovery of Aminoratjadone Derivatives as Potent Noncovalent CRM1 Inhibitors

Lunan Jian, Robert Zscherp, Ulrike Beutling, Xiaofei Shen iD, Shiyang Xu, Xia Zhang, Mark Brönstrup iD, Philipp Klahn iD, Qingxiang Sun iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c00549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Lunan Jian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, State Key Laboratory of Biotherapy and Cancer Centre, West China Hospital, Sichuan University, and Collaborative Innovation …. Hauptthemen laut MEDLINE: Carcinogenesis, Cell Nucleus. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, NaconLabs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer cells frequently utilize elevated nuclear export to escape tumor suppression and gain proliferative advantage. Chromosome Region Maintenance 1 (CRM1/XPO1) mediates macromolecule nuclear export and plays an important role in tumorigenesis and progression. The clinical approval of its covalent inhibitor KPT-330 (Selinexor) validates the feasibility of targeting CRM1 to treat cancers. Here, we synthesized four aminoratjadone derivatives and found that two of them, KL1 and KL2, are noncovalent CRM1 inhibitors. The two compounds underwent spontaneous hydrolysis in aqueous buffers, and the resulting products were more active against CRM1. High-resolution crystal structures revealed the CRM1-binding mode of these compounds and explained the observed structure-activity relationships. In cells, KL1 and KL2 localized CRM1 in the nuclear periphery and led to depletion of nuclear CRM1, thereby inhibiting the nuclear export and growth of colorectal cancer cells at submicromolar concentrations. This work lays the foundation for further development of aminoratjadone-based noncovalent CRM1 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarcinogenesisCell NucleusHumansCell Transformation, NeoplasticHydrazinesTriazoles

Substanzen

HydrazinesselinexorTriazoles

Autor:innen und Institutionen

  • Department of Pathology, State Key Laboratory of Biotherapy and Cancer Centre, West China Hospital, Sichuan University, and Collaborative Innovation Centre of Biotherapy, Chengdu 610041, China.
  • Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610056, China.
  • NaconLabs─A Technology Transfer Center of iTUBS mbH, Wilhelmsgarten 3, Braunschweig 38100, Germany.
  • Department of Chemical Biology, Helmholtz Centre for Infection Research (HZI), Braunschweig 38124, Germany.
  • TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
  • Department of Chemistry and Molecular Biology, University of Gothenburg, Kemigården 4, Göteborg 412 96, Sweden.

ORCID-Profile: Xiaofei Shen, Mark Brönstrup, Philipp Klahn, Qingxiang Sun

Förderung

  • National Natural Science Foundation of China
  • NaconLabs

Zitieren

APA

Jian, L., Zscherp, R., Beutling, U., Shen, X., Xu, S., Zhang, X., Brönstrup, M., Klahn, P., & Sun, Q. (2023). Discovery of Aminoratjadone Derivatives as Potent Noncovalent CRM1 Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00549

Vancouver

Jian L, Zscherp R, Beutling U, Shen X, Xu S, Zhang X, et al. Discovery of Aminoratjadone Derivatives as Potent Noncovalent CRM1 Inhibitors. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00549

BibTeX
@article{Jian2023,
  author = {Jian, Lunan and Zscherp, Robert and Beutling, Ulrike and Shen, Xiaofei and Xu, Shiyang and Zhang, Xia and Brönstrup, Mark and Klahn, Philipp and Sun, Qingxiang},
  title = {Discovery of Aminoratjadone Derivatives as Potent Noncovalent CRM1 Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c00549}
}
Kostenlos starten →